S. Miyakis, M. Lockshin, T. Atsumi, D. Branch, R. Brey et al., International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS), Journal of Thrombosis and Haemostasis, vol.75, issue.2, pp.295-306, 2006.
DOI : 10.1093/ajcp/103.1.103

G. Ruiz-irastorza, M. Crowther, W. Branch, and M. Khamashta, Antiphospholipid syndrome, The Lancet, vol.376, issue.9751, pp.1498-509, 2010.
DOI : 10.1016/S0140-6736(10)60709-X

M. Khamashta, M. Cuadrado, F. Mujic, N. Taub, B. Hunt et al., The Management of Thrombosis in the Antiphospholipid-Antibody Syndrome, New England Journal of Medicine, vol.332, issue.15, pp.993-1000, 1995.
DOI : 10.1056/NEJM199504133321504

J. Chen, P. Szodoray, and M. Zeher, Toll-Like Receptor Pathways in Autoimmune Diseases, Clinical Reviews in Allergy & Immunology, vol.34, issue.Suppl 1, pp.1-17, 2016.
DOI : 10.1002/eji.200324174

Y. Benhamou, J. Favre, P. Musette, S. Renet, C. Thuillez et al., Toll-like receptors 4 contribute to endothelial injury and inflammation in hemorrhagic shock in mice, Critical Care Medicine, vol.37, issue.5, pp.1724-1732, 2009.
DOI : 10.1097/CCM.0b013e31819da805

Y. Benhamou, J. Bellien, G. Armengol, E. Brakenhielm, S. Adriouch et al., Role of Toll-like Receptors 2 and 4 in Mediating Endothelial Dysfunction and Arterial Remodeling in Primary Arterial Antiphospholipid Syndrome, Arthritis & Rheumatology, vol.164, issue.11, 2014.
DOI : 10.1111/bjh.12587

S. Pierangeli, M. Vega-ostertag, E. Raschi, X. Liu, Z. Romay-penabad et al., Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies, Annals of the Rheumatic Diseases, vol.66, issue.10, pp.1327-1360, 2007.
DOI : 10.1136/ard.2006.065037

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1994302/pdf

N. Arbour, E. Lorenz, B. Schutte, J. Zabner, J. Kline et al., TLR4 mutations are associated with endotoxin hyporesponsiveness in humans, Nat Genet, vol.25, issue.2, pp.187-91, 2000.

G. Hughes, N. Harris, and A. Gharavi, The anticardiolipin syndrome, J Rheumatol, 1986.

W. Wilson, A. Gharavi, T. Koike, M. Lockshin, D. Branch et al., International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshop, Arthritis & Rheumatism, vol.7, issue.7, 1999.
DOI : 10.1191/096120398678919624

J. Piette and C. Frances, Quelle est la nature des lésions vasculaires du syndrome des antiphospholipides? Rev Médecine Interne, pp.476-80, 1993.
DOI : 10.1016/s0248-8663(05)80415-1

J. Levine, D. Branch, and J. Rauch, The Antiphospholipid Syndrome, New England Journal of Medicine, vol.346, issue.10, pp.752-63, 2002.
DOI : 10.1056/NEJMra002974

R. Cervera, J. Piette, J. Font, M. Khamashta, Y. Shoenfeld et al., Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients, Arthritis & Rheumatism, vol.15, issue.suppl 7, pp.1019-1046, 2002.
DOI : 10.1006/jaut.2000.0423

R. Cervera, R. Serrano, G. Pons-estel, L. Ceberio-hualde, Y. Shoenfeld et al., Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients, Annals of the Rheumatic Diseases, vol.82, issue.(Suppl 7), pp.1011-1019, 2015.
DOI : 10.1097/01.md.0000091181.93122.55

R. Asherson, The catastrophic antiphospholipid syndrome, J Rheumatol, 1992.

R. Cervera, J. Font, J. Gómez-puerta, G. Espinosa, M. Cucho et al., Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome, Annals of the Rheumatic Diseases, vol.64, issue.8, pp.1205-1214, 2005.
DOI : 10.1136/ard.2004.025759

D. Erkan, G. Espinosa, and R. Cervera, Catastrophic antiphospholipid syndrome: Updated diagnostic algorithms, Autoimmunity Reviews, vol.10, issue.2, pp.74-83, 2010.
DOI : 10.1016/j.autrev.2010.08.005

N. Costedoat-chalumeau, L. Coutte, L. Guern, V. Morel, N. Leroux et al., review on catastrophic antiphospholipid syndrome]. Presse Medicale Paris Fr 1983, pp.1084-92, 2016.

I. Rodríguez-pintó, M. Moitinho, I. Santacreu, Y. Shoenfeld, D. Erkan et al., Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry, Autoimmunity Reviews, vol.15, issue.12, pp.1120-1124, 2016.
DOI : 10.1016/j.autrev.2016.09.010

P. Meroni and C. Chighizola, Pathophysiology of the antiphospholipid syndrome (APS) Rev Med Interne, pp.2-4, 2012.

R. Willis and S. Pierangeli, Pathophysiology of the antiphospholipid antibody syndrome. Auto- Immun Highlights, pp.35-52, 2011.

S. Hörkkö, E. Miller, D. Branch, W. Palinski, and J. Witztum, The epitopes for some antiphospholipid antibodies are adducts of oxidized phospholipid and ??2 glycoprotein 1 (and other proteins), Proceedings of the National Academy of Sciences, vol.93, issue.16, pp.10356-61, 1997.
DOI : 10.1073/pnas.93.16.8606

P. Meroni, E. Raschi, C. Testoni, and M. Borghi, Endothelial cell activation by antiphospholipid antibodies, Clinical Immunology, vol.112, issue.2, pp.169-74, 2004.
DOI : 10.1016/j.clim.2004.02.015

J. Zhang and K. Mccrae, Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-??2 glycoprotein I antibodies, Blood, vol.105, issue.5, pp.1964-1973, 2005.
DOI : 10.1182/blood-2004-05-1708

URL : http://www.bloodjournal.org/content/bloodjournal/105/5/1964.full.pdf

P. De-groot, M. Van-lummel, M. Pennings, R. Urbanus, H. Bas-de-laat et al., Beta2-glycoprotein I and LDL-receptor family members, Thromb Res, vol.114, pp.5-6455, 2004.

M. Pennings, M. Van-lummel, R. Derksen, R. Urbanus, R. Romijn et al., -glycoprotein I with members of the low density lipoprotein receptor family, Journal of Thrombosis and Haemostasis, vol.22, issue.8, pp.1680-90, 2006.
DOI : 10.1074/jbc.M405608200

E. Raschi, C. Testoni, M. Borghi, S. Fineschi, and P. Meroni, Endothelium activation in the anti-phospholipid syndrome, Biomed Pharmacother Biomedecine Pharmacother, 2003.
DOI : 10.1016/S0753-3322(03)00083-0

N. Satta, S. Dunoyer-geindre, G. Reber, R. Fish, F. Boehlen et al., The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies. Blood, Feb, vol.15109, issue.4, pp.1507-1521, 2007.

S. Pierangeli, M. Vega-ostertag, E. Raschi, X. Liu, Z. Romay-penabad et al., Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies, Annals of the Rheumatic Diseases, vol.66, issue.10, pp.1327-1360, 2007.
DOI : 10.1136/ard.2006.065037

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1994302/pdf

R. Urbanus, B. Siegerink, M. Roest, F. Rosendaal, P. De-groot et al., Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study, The Lancet Neurology, vol.8, issue.11, 2009.
DOI : 10.1016/S1474-4422(09)70239-X

L. Rao, A. Hoang, and S. Rapaport, Mechanism and effects of the binding of lupus anticoagulant IgG and prothrombin to surface phospholipid, Blood, vol.88, issue.11, pp.4173-82, 1996.

M. Sanmarco, M. Alessi, J. Harle, C. Sapin, M. Aillaud et al., Antibodies to phosphatidylethanolamine as the only antiphospholipid antibodies found in patients with unexplained thromboses, Thromb Haemost, vol.85, issue.5, pp.800-805, 2001.

S. Dunoyer-geindre, P. De-moerloose, B. Galve-de-rochemonteix, G. Reber, and E. Kruithof, NFkappaB is an essential intermediate in the activation of endothelial cells by anti-beta(2)- glycoprotein 1 antibodies, Thromb Haemost, vol.88, issue.5, pp.851-858, 2002.

M. Vega-ostertag, K. Casper, R. Swerlick, D. Ferrara, E. Harris et al., Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies, Arthritis & Rheumatism, vol.279, issue.5, pp.1545-54, 2005.
DOI : 10.1016/S0002-9378(12)90915-1

E. Raschi, C. Testoni, D. Bosisio, M. Borghi, T. Koike et al., Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies, Blood, vol.101, issue.9, pp.3495-500, 2003.
DOI : 10.1182/blood-2002-08-2349

G. Kaplanski, P. Cacoub, C. Farnarier, V. Marin, R. Grégoire et al., Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: Correlations with the severity of thrombosis, Arthritis & Rheumatism, vol.44, issue.1, pp.55-64, 2000.
DOI : 10.1038/ki.1993.315

S. Pierangeli, R. Espinola, X. Liu, and E. Harris, Thrombogenic Effects of Antiphospholipid Antibodies Are Mediated by Intercellular Cell Adhesion Molecule-1, Vascular Cell Adhesion Molecule-1, and P-Selectin, Circulation Research, vol.88, issue.2, pp.245-50, 2001.
DOI : 10.1161/01.RES.88.2.245

A. Kinev and R. A. Roubey, Tissue factor in the antiphospholipid syndrome, Lupus, vol.110, issue.10, pp.952-960, 2008.
DOI : 10.1161/01.CIR.0000136027.98303.4D

K. Ahmed, J. Vianna, M. Khamashta, and G. Hughes, IL-2, IL-6 and TNF levels in primary antiphospholipid syndrome, Clin Exp Rheumatol, vol.10, issue.5, p.503, 1992.

B. De-laat, X. Wu, M. Van-lummel, R. Derksen, P. De-groot et al., Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood, Feb, vol.15109, issue.4, pp.1490-1494, 2007.

G. Cesarman-maus, N. Ríos-luna, A. Deora, B. Huang, R. Villa et al., Autoantibodies against the fibrinolytic receptor, antiphospholipid syndrome. Blood, pp.4375-82, 2006.
DOI : 10.1182/blood-2005-07-2636

URL : http://www.bloodjournal.org/content/bloodjournal/107/11/4375.full.pdf

M. Adams, S. Donohoe, I. Mackie, and S. Machin, Anti-tissue factor pathway inhibitor activity in patients with primary antiphospholipid syndrome, British Journal of Haematology, vol.5, issue.2, pp.375-384, 2001.
DOI : 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F

URL : http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2141.2001.02923.x/pdf

M. Galli, D. Luciani, G. Bertolini, and T. Barbui, Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature, Blood, vol.101, issue.5, pp.1827-1859, 2003.
DOI : 10.1182/blood-2002-02-0441

V. Pengo, A. Ruffatti, C. Legnani, S. Testa, T. Fierro et al., Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study, Blood, vol.118, issue.17, pp.4714-4722, 2011.
DOI : 10.1182/blood-2011-03-340232

G. Moulis, A. Audemard-verger, L. Arnaud, C. Luxembourger, F. Montastruc et al., Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies: A systematic review and meta-analysis, Autoimmunity Reviews, vol.15, issue.3, pp.203-212, 2016.
DOI : 10.1016/j.autrev.2015.11.001

D. Wahl, F. Guillemin, E. De-maistre, C. Perret-guillaume, T. Lecompte et al., Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis, Lupus, vol.333, issue.1, pp.15-22, 1998.
DOI : 10.1056/NEJM199509073331016

S. Schulman, E. Svenungsson, and S. Granqvist, Anticardiolipin Antibodies Predict Early Recurrence of Thromboembolism and Death Among Patients with Venous Thromboembolism Following Anticoagulant Therapy, The American Journal of Medicine, vol.104, issue.4, pp.332-340, 1998.
DOI : 10.1016/S0002-9343(98)00060-6

P. Mustonen, K. Lehtonen, K. Javela, and M. Puurunen, Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study, Lupus, vol.86, issue.14, pp.1468-76, 2014.
DOI : 10.1055/s-0029-1242716

M. Galli, Antiphospholipid antibodies and thrombosis: do test patterns identify the patients' risk?, Thrombosis Research, vol.114, issue.5-6, pp.5-6597, 2004.
DOI : 10.1016/j.thromres.2004.08.009

J. Rodriguez-garcia, M. Bertolaccini, M. Cuadrado, G. Sanna, O. Ateka-barrutia et al., Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called ???seronegative APS???), Annals of the Rheumatic Diseases, vol.71, issue.2, pp.242-246, 2012.
DOI : 10.1136/annrheumdis-2011-200614

K. Duckitt and D. Harrington, Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies, BMJ, vol.330, issue.7491, p.565, 2005.
DOI : 10.1136/bmj.38380.674340.E0

J. Nodler, S. Moolamalla, E. Ledger, B. Nuwayhid, and Z. Mulla, Elevated antiphospholipid antibody titers and adverse pregnancy outcomes: analysis of a population-based hospital dataset, BMC Pregnancy and Childbirth, vol.100, issue.1, p.11, 2009.
DOI : 10.1016/S0029-7844(02)02165-8

L. Opatrny, M. David, S. Kahn, I. Shrier, and E. Rey, Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis, J Rheumatol, vol.33, issue.11, pp.2214-2235, 2006.

A. Ruffatti, M. Tonello, M. Visentin, A. Bontadi, A. Hoxha et al., Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study, Rheumatology, vol.50, issue.9, pp.1684-1693, 2011.
DOI : 10.1093/rheumatology/ker139

G. Ruiz-irastorza, M. Cuadrado, I. Ruiz-arruza, R. Brey, M. Crowther et al., Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a Task Force at the 13th International Congress on Antiphospholipid Antibodies, Lupus, vol.1173, issue.2, pp.206-224, 2011.
DOI : 10.1111/j.1538-7836.2009.03588.x

D. Erkan, M. Harrison, R. Levy, M. Peterson, M. Petri et al., Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody???positive individuals, Arthritis & Rheumatism, vol.113, issue.7, pp.2382-91, 2007.
DOI : 10.1136/bmj.309.6963.1215

L. Arnaud, A. Mathian, H. Devilliers, A. Ruffatti, M. Tektonidou et al., Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies, Autoimmunity Reviews, vol.14, issue.3, pp.192-200
DOI : 10.1016/j.autrev.2014.10.019

M. Tektonidou, K. Laskari, D. Panagiotakos, and H. Moutsopoulos, Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum, pp.29-36, 2009.

T. Tarr, G. Lakos, H. Bhattoa, P. Soltesz, Y. Shoenfeld et al., Clinical Thrombotic Manifestations in SLE Patients With and Without Antiphospholipid Antibodies: A 5-year Follow-up, Clinical Reviews in Allergy & Immunology, vol.2, issue.1, pp.131-138, 2007.
DOI : 10.7326/0003-4819-117-4-303

D. Wahl, H. Bounameaux, P. De-moerloose, and F. Sarasin, Prophylactic Antithrombotic Therapy for Patients With Systemic Lupus Erythematosus With or Without Antiphospholipid Antibodies, Archives of Internal Medicine, vol.160, issue.13, pp.2042-2050, 2000.
DOI : 10.1001/archinte.160.13.2042

URL : http://archinte.jamanetwork.com/data/journals/intemed/11967/ioi90546.pdf

G. Ruiz-irastorza, M. Ramos-casals, P. Brito-zeron, and M. Khamashta, Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review, Annals of the Rheumatic Diseases, vol.69, issue.01, pp.20-28, 2010.
DOI : 10.1136/ard.2008.101766

J. Szymezak, A. Ankri, A. Fischer, and L. Darnige, Hydroxychloroquine??: une nouvelle approche th??rapeutique des manifestations thrombotiques du syndrome des antiphospholipides, La Revue de M??decine Interne, vol.31, issue.12, pp.854-861, 2010.
DOI : 10.1016/j.revmed.2010.08.018

M. Rosove and P. Brewer, Antiphospholipid Thrombosis: Clinical Course after the First Thrombotic Event in 70 Patients, Annals of Internal Medicine, vol.117, issue.4, pp.303-311, 1992.
DOI : 10.7326/0003-4819-117-4-303

M. Crowther, J. Ginsberg, J. Julian, J. Denburg, J. Hirsh et al., A Comparison of Two Intensities of Warfarin for the Prevention of Recurrent Thrombosis in Patients with the Antiphospholipid Antibody Syndrome, New England Journal of Medicine, vol.349, issue.12, pp.1133-1141, 2003.
DOI : 10.1056/NEJMoa035241

G. Finazzi, R. Marchioli, V. Brancaccio, P. Schinco, F. Wisloff et al., A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)1, Journal of Thrombosis and Haemostasis, vol.68, issue.5, pp.848-53, 2005.
DOI : 10.1001/jama.291.5.576

G. Ruiz-irastorza, B. Hunt, and M. Khamashta, A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum, pp.1487-95, 2007.

C. Kearon, M. Gent, J. Hirsh, J. Weitz, M. Kovacs et al., A Comparison of Three Months of Anticoagulation with Extended Anticoagulation for a First Episode of Idiopathic Venous Thromboembolism, New England Journal of Medicine, vol.340, issue.12, pp.901-908, 1999.
DOI : 10.1056/NEJM199903253401201

R. Glynn, E. Danielson, F. Fonseca, J. Genest, A. Gotto et al., A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism, New England Journal of Medicine, vol.360, issue.18, pp.1851-61, 2009.
DOI : 10.1056/NEJMoa0900241

V. Pengo, A. Ruffatti, C. Legnani, S. Testa, T. Fierro et al., Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study, Blood, vol.118, issue.17, pp.4714-4722, 2011.
DOI : 10.1182/blood-2011-03-340232

M. Galli, D. Luciani, G. Bertolini, and T. Barbui, Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature, Blood, vol.101, issue.5, pp.1827-1859, 2003.
DOI : 10.1182/blood-2002-02-0441

M. Tektonidou, K. Laskari, D. Panagiotakos, and H. Moutsopoulos, Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum, pp.29-36, 2009.

D. Erkan, C. Aguiar, D. Andrade, H. Cohen, M. Cuadrado et al., 14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends, 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends, pp.685-96
DOI : 10.1016/j.autrev.2014.01.053

D. Erkan, J. Vega, G. Ramón, E. Kozora, and M. Lockshin, A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome, Arthritis & Rheumatism, vol.12, issue.2, pp.464-71, 2013.
DOI : 10.1191/0961203303lu409oa

I. Pons, G. Espinosa, and R. Cervera, Efficacy and safety of rituximab in the treatment of primary antiphospholipid syndrome: Analysis of 24 cases from the bibliography review, Medicina Cl??nica (English Edition), vol.144, issue.3, pp.97-104, 2015.
DOI : 10.1016/j.medcle.2015.05.012

H. Cohen, B. Hunt, M. Efthymiou, D. Arachchillage, I. Mackie et al., Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial, The Lancet Haematology, vol.3, issue.9, pp.426-436, 2016.
DOI : 10.1016/S2352-3026(16)30079-5

V. Pengo, A. Banzato, E. Bison, G. Zoppellaro, P. Jose et al., Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial, Lupus, vol.95, issue.3, pp.301-307, 2016.
DOI : 10.1111/jth.12264

S. Woller, S. Stevens, D. Kaplan, D. Branch, V. Aston et al., Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome, Clinical and Applied Thrombosis/Hemostasis, vol.3, issue.1, pp.239-286
DOI : 10.1016/j.jbi.2008.08.010

S. Bucciarelli, R. Cervera, G. Espinosa, J. Gómez-puerta, M. Ramos-casals et al., Mortality in the catastrophic antiphospholipid syndrome: Causes of death and prognostic factors, Autoimmunity Reviews, vol.6, issue.2, pp.72-77, 2006.
DOI : 10.1016/j.autrev.2006.06.007

S. Sciascia, O. Giachino, and D. Roccatello, Prevention of thrombosis relapse in antiphospholipid syndrome patients refractory to conventional therapy using intravenous immunoglobulin, Clin Exp Rheumatol. 2012, vol.30, issue.3, pp.409-422

H. Berman, I. Rodríguez-pintó, R. Cervera, N. Morel, N. Costedoat-chalumeau et al., Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab, Autoimmunity Reviews, vol.12, issue.11, pp.1085-90, 2013.
DOI : 10.1016/j.autrev.2013.05.004

I. Shapira, D. Andrade, S. Allen, and J. Salmon, Brief Report: Induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab, Arthritis & Rheumatism, vol.362, issue.8, pp.2719-2742, 2012.
DOI : 10.1056/NEJMc0910965

A. Kronbichler, R. Frank, M. Kirschfink, Á. Szilágyi, D. Csuka et al., Efficacy of Eculizumab in a Patient With Immunoadsorption-Dependent Catastrophic Antiphospholipid Syndrome, Medicine, vol.93, issue.26, p.143, 2014.
DOI : 10.1097/MD.0000000000000143

M. Strakhan, M. Hurtado-sbordoni, N. Galeas, K. Bakirhan, A. K. Elrafei et al., 36-Year-Old Female with Catastrophic Antiphospholipid Syndrome Treated with Eculizumab: A Case Report and Review of Literature, Case Reports in Hematology, vol.2014, p.704371, 2014.
DOI : 10.1182/blood-2005-03-1319

T. Zikos, J. Sokolove, N. Ahuja, and C. Berube, Eculizumab Induces Sustained Remission in a Patient With Refractory Primary Catastrophic Antiphospholipid Syndrome, JCR: Journal of Clinical Rheumatology, vol.21, issue.6, pp.311-314, 2015.
DOI : 10.1097/RHU.0000000000000290

P. Ziakas, M. Pavlou, and M. Voulgarelis, Heparin Treatment in Antiphospholipid Syndrome With Recurrent Pregnancy Loss, Obstetrics & Gynecology, vol.115, issue.6, 2010.
DOI : 10.1097/AOG.0b013e3181deba40

A. Mak, M. Cheung, A. Cheak, and R. Ho, Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression, Rheumatology, vol.49, issue.2, pp.281-289, 2010.
DOI : 10.1093/rheumatology/kep373

C. Hashimoto, K. Hudson, and K. Anderson, The Toll gene of Drosophila, required for dorsalventral embryonic polarity, appears to encode a transmembrane protein. Cell, pp.269-79, 1988.

B. Lemaitre, E. Nicolas, L. Michaut, J. Reichhart, and J. Hoffmann, The Dorsoventral Regulatory Gene Cassette sp??tzle/Toll/cactus Controls the Potent Antifungal Response in Drosophila Adults, Cell, vol.86, issue.6, pp.973-83, 1996.
DOI : 10.1016/S0092-8674(00)80172-5

R. Medzhitov, P. Preston-hurlburt, and C. Janeway, A human homologue of the Drosophila Toll protein signals activation of adaptive immunity, Nature, vol.254, issue.6640, pp.394-401, 1997.
DOI : 10.1126/science.1925582

A. Abdelsadik and A. Trad, Toll-like receptors on the fork roads between innate and adaptive immunity, Human Immunology, vol.72, issue.12, pp.1188-93, 2011.
DOI : 10.1016/j.humimm.2011.08.015

K. Takeda and S. Akira, Toll-like receptors, Curr Protoc Immunol, vol.109, pp.14-26, 2015.
DOI : 10.1002/0471142735.im1412s109

M. Essakalli, O. Atouf, N. Bennani, N. Benseffaj, S. Ouadghiri et al., Toll-like r??cepteurs, Pathologie Biologie, vol.57, issue.5, pp.430-438, 2009.
DOI : 10.1016/j.patbio.2008.04.003

W. Strober, P. Murray, A. Kitani, and T. Watanabe, Signalling pathways and molecular interactions of NOD1 and NOD2, Nature Reviews Immunology, vol.1029, issue.1, pp.9-20, 2006.
DOI : 10.4049/jimmunol.170.3.1406

O. Neill, L. Bowie, and A. , The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling, Nature Reviews Immunology, vol.19, issue.5, pp.353-64, 2007.
DOI : 10.4049/jimmunol.175.2.839

T. Kawai and S. Akira, Toll-like receptor downstream signaling, Arthritis Research & Therapy, vol.7, issue.1, pp.12-21, 2005.
DOI : 10.1186/ar1469

S. Drexler and B. Foxwell, The role of Toll-like receptors in chronic inflammation, The International Journal of Biochemistry & Cell Biology, vol.42, issue.4, pp.506-524
DOI : 10.1016/j.biocel.2009.10.009

D. Xu, H. Liu, and M. Komai-koma, Direct and indirect role of Toll-like receptors in T cell mediated immunity, Cell Mol Immunol, vol.1, issue.4, pp.239-285, 2004.

B. Park, D. Song, H. Kim, B. Choi, H. Lee et al., The structural basis of lipopolysaccharide recognition by the TLR4???MD-2 complex, Nature, vol.50, issue.7242, pp.1191-1196, 2009.
DOI : 10.4049/jimmunol.181.2.1245

Y. Nagai, S. Akashi, M. Nagafuku, M. Ogata, Y. Iwakura et al., Essential role of MD-2 in LPS responsiveness and TLR4 distribution, Nature Immunology, vol.7, issue.7, pp.667-72, 2002.
DOI : 10.1038/sj.gt.3301206

J. Imler and J. Hoffmann, Toll receptors in innate immunity, Trends in Cell Biology, vol.11, issue.7, 2001.
DOI : 10.1016/S0962-8924(01)02004-9

B. Pulendran, Modulating vaccine responses with dendritic cells and Toll-like receptors, Immunological Reviews, vol.171, issue.1, pp.227-50, 2004.
DOI : 10.1038/ni962

J. Banchereau, F. Briere, C. Caux, J. Davoust, S. Lebecque et al., Immunobiology of Dendritic Cells, Annual Review of Immunology, vol.18, issue.1, pp.767-811, 2000.
DOI : 10.1146/annurev.immunol.18.1.767

C. Pasare and R. Medzhitov, Control of B-cell responses by Toll-like receptors, Nature, vol.4, issue.7066, pp.364-372, 2005.
DOI : 10.1016/0008-8749(72)90043-3

T. Barr, S. Brown, G. Ryan, J. Zhao, and D. Gray, TLR-mediated stimulation of APC: Distinct cytokine responses of B cells and dendritic cells, European Journal of Immunology, vol.176, issue.11, 2007.
DOI : 10.4049/jimmunol.172.5.3252

S. Levy, G. Sutton, P. Ng, L. Feuk, A. Halpern et al., The Diploid Genome Sequence of an Individual Human, PLoS Biology, vol.17, issue.10, p.254, 2007.
DOI : 10.1371/journal.pbio.0050254.sd001

P. Cristofaro and S. Opal, Role of Toll-Like Receptors in Infection and Immunity, Drugs, vol.8, issue.2, pp.15-29, 2006.
DOI : 10.4049/jimmunol.174.5.2942

M. Tsan, Toll-like receptors, inflammation and cancer. Semin Cancer Biol, Feb, vol.16, issue.1, pp.32-39, 2006.

S. Rakoff-nahoum and R. Medzhitov, Toll-like receptors and cancer, Nature Reviews Cancer, vol.5, issue.1, pp.57-63, 2009.
DOI : 10.1182/blood-2007-05-088682

M. Borghi, E. Raschi, C. Grossi, C. Chighizola, and P. Meroni, glycoprotein I interaction on endothelial cells, Lupus, vol.23, issue.12, pp.1302-1306, 2014.
DOI : 10.1182/blood-2011-01-333617

H. Zhou, Y. Yan, G. Xu, B. Zhou, H. Wen et al., Toll-like receptor (TLR)-4 mediates anti-??2GPI/??2GPI-induced tissue factor expression in THP-1 cells, Clinical & Experimental Immunology, vol.185, issue.2, pp.189-98, 2011.
DOI : 10.4049/jimmunol.1000526

URL : http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2249.2010.04291.x/pdf

G. Pasterkamp, J. Van-keulen, D. Kleijn, and D. , Role of Toll-like receptor 4 in the initiation and progression of atherosclerotic disease, European Journal of Clinical Investigation, vol.168, issue.5, pp.328-362, 2004.
DOI : 10.4049/jimmunol.168.3.1435

K. Hoshino, O. Takeuchi, T. Kawai, H. Sanjo, T. Ogawa et al., Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product, J Immunol Baltim Md, vol.162, issue.7, pp.3749-52, 1950.

B. Liu, Y. Yang, J. Dai, R. Medzhitov, M. Freudenberg et al., TLR4 upregulation at protein or gene level is pathogenic for lupus-like autoimmune disease, J Immunol Baltim Md, vol.177, issue.10, pp.6880-6888, 1950.
DOI : 10.4049/jimmunol.177.10.6880

URL : http://www.jimmunol.org/content/jimmunol/177/10/6880.full.pdf

A. Lartigue, N. Colliou, S. Calbo, A. François, S. Jacquot et al., Critical role of TLR2 and TLR4 in autoantibody production and glomerulonephritis in lpr mutationinduced mouse lupus, J Immunol Baltim Md, vol.183, issue.10, pp.6207-6223, 1950.

S. Devaraj, M. Dasu, S. Park, and I. Jialal, Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes, Diabetologia, vol.292, issue.8, pp.1665-1673, 2009.
DOI : 10.1007/s00125-009-1394-8

E. Zaharieva, Z. Kamenov, and A. Savov, Abstract, Endocrine Regulations, vol.15, issue.3, pp.137-181, 2017.
DOI : 10.1515/enr-2017-0014

R. Kaiser, L. Tang, K. Taylor, K. Sterba, J. Nititham et al., A polymorphism in TLR2 is associated with arterial thrombosis in a multiethnic population of patients with systemic lupus erythematosus, Arthritis Rheumatol Hoboken NJ. 2014, vol.66, issue.7, pp.1882-1889

J. Hurst, N. Prinz, M. Lorenz, S. Bauer, J. Chapman et al., TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-1?? and caspase-1 in monocytes and dendritic cells, Immunobiology, vol.214, issue.8, pp.683-91, 2009.
DOI : 10.1016/j.imbio.2008.12.003

Y. Döring, J. Hurst, M. Lorenz, N. Prinz, N. Clemens et al., Human antiphospholipid antibodies induce TNF?? in monocytes via Toll-like receptor 8, Immunobiology, vol.215, issue.3, pp.230-271, 2010.
DOI : 10.1016/j.imbio.2009.03.002

S. Gysler, M. Mulla, M. Guerra, J. Brosens, J. Salmon et al., Antiphospholipid antibody-induced miR-146a-3p drives trophoblast interleukin-8 secretion through activation of Toll-like receptor 8, Molecular Human Reproduction, vol.22, issue.7, pp.465-74
DOI : 10.1093/molehr/gaw027

D. Saadoun, J. Piette, D. Wahl, and N. Costedoat-chalumeau, Traitement du syndrome des anticorps antiphospholipides, La Revue de M??decine Interne, vol.33, issue.4, pp.217-239
DOI : 10.1016/j.revmed.2012.01.007

J. Roth and C. Blatteis, Mechanisms of Fever Production and Lysis: Lessons from Experimental LPS Fever, Compr Physiol, vol.856, issue.2, pp.1563-604, 2014.
DOI : 10.1111/j.1749-6632.1998.tb08311.x